Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to Cytosorbents' second quarter earnings call conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call, you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, August 6, 2026. I would now like to turn the conference over to Pete Mariani. Please go ahead. Thank you, Matthew, and good afternoon, everyone. Welcome to Cytosorbents' second quarter 2026 conference call. Joining me today is Dr. Phillip Chan, our chief executive officer, Dr. Micah Deliargyris, our chief medical officer. During today's call, we will have an overview presentation covering the operating and financial highlights for the second quarter of 2026. and a review of our four key drivers of value creation, including a regulatory update on our process to obtain U.S. marketing approval for DrugSorb ATR. Following the presentation, we will open the lines to analysts for questions. Before I turn the call over to Phil, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements, which are subject to risks and uncertainty. Management may make additional forward-looking statements in response to your questions. Therefore, the company claims protection under the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from results discussed today. The forward-looking statements we make today may reflect our reviews and estimates as of today, August 6, 2026, and we assume no obligation to update these obligations in the future as market conditions change...